公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial | Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; CHIA-CHI LIN ; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. | Journal of Thoracic Oncology | 112 | 101 | |
2019 | Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium | Huang C.-F.; Iio E.; Jun D.W.; Ogawa E.; Toyoda H.; Hsu Y.-C.; Haga H.; Iwane S.; Enomoto M.; Lee D.H.; Wong G.; CHEN-HUA LIU ; Tada T.; Chuang W.-L.; Cheung R.; Hayashi J.; Tseng C.-H.; Yasuda S.; Tran S.; Kam L.; Henry L.; Jeong J.Y.; Nomura H.; Park S.H.; Nakamuta M.; Huang J.-F.; Tai C.-M.; Lo G.-H.; Lee M.-H.; Yang H.-I.; JIA-HORNG KAO ; Tamori A.; Eguchi Y.; Ueno Y.; Furusyo N.; Tanaka Y.; Yu M.-L.; Nguyen M.H.; For the REAL-C Investigators | Hepatology International | 31 | 27 | |
2020 | Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: A practice implication | Ogawa E.; Toyoda H.; Iio E.; Jun D.W.; Huang C.-F.; Enomoto M.; Hsu Y.-C.; Haga H.; Iwane S.; Wong G.; Lee D.H.; Tada T.; CHEN-HUA LIU ; Chuang W.-L.; Hayashi J.; Cheung R.; Yasuda S.; Tseng C.-H.; Takahashi H.; Tran S.; Yeo Y.H.; Henry L.; Barnett S.D.; Nomura H.; Nakamuta M.; Dai C.-Y.; Huang J.-F.; Yang H.-I.; Lee M.-H.; Jun M.J.; JIA-HORNG KAO ; Eguchi Y.; Ueno Y.; Tamori A.; Furusyo N.; Yu M.-L.; Tanaka Y.; Nguyen M.H.; Ahn S.B.; Azuma K.; Dohmen K.; Jeong J.Y.; Jung J.H.; Kajiwara E.; Kato M.; Kawano A.; Koyanagi T.; Ooho A.; Park S.H.; Satoh T.; Shimoda S.; Song D.S.; Takahashi K.; Yeh M.-L.; Yoon E.L.; Real-World Evidence from the Asia Liver Consortium Investigators | Clinical Infectious Diseases | 26 | 19 | |
2021 | Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study | Park K.; Jӓnne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU ; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. | Cancer | 18 | 10 | |
2021 | Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer | Yu H.A.; Paz-Ares L.G.; CHIH-HSIN YANG ; Lee K.H.; Garrido P.; Park K.; Kim J.-H.; Lee D.H.; Mao H.; Wijayawardana S.R.; Gao L.; Hozak R.R.; Chao B.H.; Planchard D. | Clinical Cancer Research | 34 | 30 |